This is a Phase 3 study to assess the efficacy and safety of twice-weekly subcutaneous (SC) doses of pegcetacoplan compared to placebo in patients with C3 glomerulopathy (C3G) or immune-complex membranoproliferative glomerulonephritis (IC-MPGN) on…
- Investigator
- Lawrence R Shoemaker
- Status
- Accepting Candidates
- Ages
- 12 Years - N/A
- Sexes
- All